106 related articles for article (PubMed ID: 26717939)
1. Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence.
Jo JK; Kim K; Lee SE; Lee JK; Byun SS; Hong SK
Ann Surg Oncol; 2016 May; 23(5):1760-7. PubMed ID: 26717939
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Phosphodiesterase 5 Inhibitor on Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer.
Chung JW; Kim JW; Ha YS; Choi SH; Lee JN; Kim BS; Kim HT; Yoo ES; Kwon TG; Kim TH
Urol J; 2019 Jun; 16(3):255-259. PubMed ID: 31204438
[TBL] [Abstract][Full Text] [Related]
3. Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?
Flores JM; Vertosick E; Jenkins LC; Cooper J; Benfante N; Sjoberg D; Vickers AJ; Eastham JA; Laudone VP; Scardino PT; Nelson CJ; Mulhall JP
J Urol; 2024 Mar; 211(3):400-406. PubMed ID: 38194487
[TBL] [Abstract][Full Text] [Related]
4. Is there a relationship between phosphodiesterase type 5 inhibitors and biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis.
He Q; Liao BH; Xiao KW; Zhou L; Feng SJ; Li H; Wang KJ
Int Urol Nephrol; 2018 Dec; 50(12):2113-2121. PubMed ID: 30232722
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
[TBL] [Abstract][Full Text] [Related]
6. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
[TBL] [Abstract][Full Text] [Related]
7. Sexual Rehabilitation After Nerve-Sparing Radical Prostatectomy: Free-of-Charge Phosphodiesterase Type 5 Inhibitor Administration Improves Compliance to Treatment.
Siena G; Mari A; Canale A; Mondaini N; Chindemi A; Greco I; Saleh O; Serni S; Nicita G; Minervini A; Carini M
J Sex Med; 2018 Feb; 15(2):120-123. PubMed ID: 29425663
[TBL] [Abstract][Full Text] [Related]
8. Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy.
Kimura M; Caso JR; Bañez LL; Koontz BF; Gerber L; Senocak C; Donatucci CF; Vujaskovic Z; Moul JW; Polascik TJ
BJU Int; 2012 Dec; 110(11 Pt C):E931-8. PubMed ID: 22520165
[TBL] [Abstract][Full Text] [Related]
9. A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy.
Gallina A; Bianchi M; Gandaglia G; Cucchiara V; Suardi N; Montorsi F; Briganti A
Eur Urol; 2015 Nov; 68(5):750-3. PubMed ID: 25700565
[TBL] [Abstract][Full Text] [Related]
10. Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy.
Michl U; Molfenter F; Graefen M; Tennstedt P; Ahyai S; Beyer B; Budäus L; Haese A; Heinzer H; Oh SJ; Salomon G; Schlomm T; Steuber T; Thederan I; Huland H; Tilki D
J Urol; 2015 Feb; 193(2):479-83. PubMed ID: 25196656
[TBL] [Abstract][Full Text] [Related]
11. Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review.
Aoun F; Slaoui A; Walid AHO; Albisinni S; Assenmacher G; de Plaen E; Azzo JM; Peltier A; Roumeguère T
Prog Urol; 2018 Oct; 28(12):560-566. PubMed ID: 30201551
[TBL] [Abstract][Full Text] [Related]
12. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function.
Basal S; Wambi C; Acikel C; Gupta M; Badani K
BJU Int; 2013 Apr; 111(4):658-65. PubMed ID: 23186312
[TBL] [Abstract][Full Text] [Related]
13. Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: a single center study.
Cattarino S; Seisen T; Drouin SJ; Renard-Penna R; Leon P; Comperat E; Mozer P; Cussenot O; Rouprêt M
Can J Urol; 2015 Apr; 22(2):7703-8. PubMed ID: 25891333
[TBL] [Abstract][Full Text] [Related]
14. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy.
Rieken M; Shariat SF; Kluth LA; Fajkovic H; Rink M; Karakiewicz PI; Seitz C; Briganti A; Rouprêt M; Loidl W; Trinh QD; Bachmann A; Pourmand G
Eur Urol; 2015 Dec; 68(6):949-56. PubMed ID: 26050111
[TBL] [Abstract][Full Text] [Related]
15. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
16. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy.
Chao C; Jacobsen SJ; Xu L; Wallner LP; Porter KR; Williams SG
BJU Int; 2013 May; 111(6):954-62. PubMed ID: 23464862
[TBL] [Abstract][Full Text] [Related]
17. Radical prostatectomy in clinically localized high-risk prostate cancer: outcome of 231 consecutive patients.
Røder MA; Berg KD; Christensen IJ; Gruschy L; Brasso K; Iversen P
Scand J Urol; 2013 Feb; 47(1):19-25. PubMed ID: 22762145
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of positive surgical margins after radical prostatectomy among pT2 and pT3a prostate cancer.
Oh JJ; Hong SK; Byun SS; Choe G; Lee SE
Urol Oncol; 2013 Jul; 31(5):595-600. PubMed ID: 21658977
[TBL] [Abstract][Full Text] [Related]
19. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
Moschini M; Sharma V; Zattoni F; Quevedo JF; Davis BJ; Kwon E; Karnes RJ
Eur Urol; 2016 Jan; 69(1):135-42. PubMed ID: 25865061
[TBL] [Abstract][Full Text] [Related]
20. Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes.
Danzig MR; Kotamarti S; Ghandour RA; Rothberg MB; Dubow BP; Benson MC; Badani KK; McKiernan JM
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):63-8. PubMed ID: 25403419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
